AU2008304657B2 - Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity - Google Patents
Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity Download PDFInfo
- Publication number
- AU2008304657B2 AU2008304657B2 AU2008304657A AU2008304657A AU2008304657B2 AU 2008304657 B2 AU2008304657 B2 AU 2008304657B2 AU 2008304657 A AU2008304657 A AU 2008304657A AU 2008304657 A AU2008304657 A AU 2008304657A AU 2008304657 B2 AU2008304657 B2 AU 2008304657B2
- Authority
- AU
- Australia
- Prior art keywords
- heteroaryl
- substituted
- sphingosine
- compound
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97451107P | 2007-09-24 | 2007-09-24 | |
| US60/974,511 | 2007-09-24 | ||
| PCT/US2008/076792 WO2009042485A1 (en) | 2007-09-24 | 2008-09-18 | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2008304657A1 AU2008304657A1 (en) | 2009-04-02 |
| AU2008304657B2 true AU2008304657B2 (en) | 2013-09-05 |
Family
ID=40042883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2008304657A Ceased AU2008304657B2 (en) | 2007-09-24 | 2008-09-18 | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7888336B2 (enExample) |
| EP (1) | EP2203424A1 (enExample) |
| JP (1) | JP2010540543A (enExample) |
| KR (1) | KR20100067677A (enExample) |
| CN (1) | CN101918360A (enExample) |
| AU (1) | AU2008304657B2 (enExample) |
| BR (1) | BRPI0817397A2 (enExample) |
| CA (1) | CA2700539A1 (enExample) |
| RU (1) | RU2010112275A (enExample) |
| WO (1) | WO2009042485A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2006088246A1 (ja) * | 2005-02-18 | 2008-07-10 | 武田薬品工業株式会社 | Gpr34受容体機能調節剤 |
| US8524917B2 (en) * | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
| AU2012245683A1 (en) * | 2011-04-18 | 2013-11-07 | Allergan, Inc. | Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators |
| GB201603745D0 (en) * | 2016-03-04 | 2016-04-20 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007112322A2 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4363912A (en) * | 1980-12-15 | 1982-12-14 | Pfizer Inc. | Indole thromboxane synthetase inhibitors |
| EP0146810A3 (de) * | 1983-12-05 | 1987-05-13 | Solco Basel AG | Verfahren zur Herstellung von Sphingosinderivaten |
| US5110987A (en) * | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
| ZA902794B (en) * | 1989-04-18 | 1991-04-24 | Duphar Int Res | New 3-n substituted carbamoyl-indole derivatives |
| US5294722A (en) * | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5403851A (en) * | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
| US5639780A (en) * | 1995-05-22 | 1997-06-17 | Merck Frosst Canada, Inc. | N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors |
| US5811425A (en) * | 1997-03-04 | 1998-09-22 | Abbott Laboratories | Heterocyclic compounds as COX-2 inhibitors |
| US6235912B1 (en) * | 1997-03-12 | 2001-05-22 | Takara Shuzo Co., Ltd. | Sphingosine analogues |
| JP4091250B2 (ja) * | 1997-09-11 | 2008-05-28 | タカラバイオ株式会社 | スフィンゴシン類誘導体及び医薬組成物 |
| US6358992B1 (en) * | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
| FR2814073B1 (fr) * | 2000-09-21 | 2005-06-24 | Yang Ji Chemical Company Ltd | Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition |
| DE60221391T2 (de) * | 2001-06-20 | 2008-04-17 | Wyeth | Substituierte indolsäurederivate als inhibitoren von plasminogen-aktivator-inhibitor-1 (pai-1) |
| JP2005519915A (ja) | 2002-01-18 | 2005-07-07 | セレテック・リミテッド・ライアビリティ・カンパニー | Edg受容体に関連する症状の処置方法 |
| ATE441654T1 (de) | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| JP4505449B2 (ja) | 2003-02-11 | 2010-07-21 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 新規二環式化合物および組成物 |
| ATE547395T1 (de) | 2003-04-30 | 2012-03-15 | Novartis Pharma Gmbh | Aminopropanol-derivate als modulatoren des sphingosin-1-phosphat-rezeptors |
| MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
| US7582773B2 (en) * | 2003-09-25 | 2009-09-01 | Wyeth | Substituted phenyl indoles |
| CA2642668C (en) * | 2006-02-15 | 2013-01-08 | Allergan, Inc. | Indole-3-carboxylic acid amide and ester compounds bearing phenyl groups having sphingosine-1-phosphate (s1p) receptor antagonist biological activity |
-
2008
- 2008-09-18 CN CN2008801163102A patent/CN101918360A/zh active Pending
- 2008-09-18 RU RU2010112275/04A patent/RU2010112275A/ru unknown
- 2008-09-18 KR KR1020107008739A patent/KR20100067677A/ko not_active Withdrawn
- 2008-09-18 JP JP2010527035A patent/JP2010540543A/ja active Pending
- 2008-09-18 EP EP08833361A patent/EP2203424A1/en not_active Withdrawn
- 2008-09-18 CA CA2700539A patent/CA2700539A1/en not_active Abandoned
- 2008-09-18 AU AU2008304657A patent/AU2008304657B2/en not_active Ceased
- 2008-09-18 US US12/679,530 patent/US7888336B2/en not_active Expired - Fee Related
- 2008-09-18 BR BRPI0817397 patent/BRPI0817397A2/pt not_active IP Right Cessation
- 2008-09-18 WO PCT/US2008/076792 patent/WO2009042485A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007112322A2 (en) * | 2006-03-28 | 2007-10-04 | Allergan, Inc. | Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100067677A (ko) | 2010-06-21 |
| EP2203424A1 (en) | 2010-07-07 |
| RU2010112275A (ru) | 2011-11-10 |
| AU2008304657A1 (en) | 2009-04-02 |
| JP2010540543A (ja) | 2010-12-24 |
| US20100240614A1 (en) | 2010-09-23 |
| CN101918360A (zh) | 2010-12-15 |
| US7888336B2 (en) | 2011-02-15 |
| CA2700539A1 (en) | 2009-04-02 |
| WO2009042485A1 (en) | 2009-04-02 |
| BRPI0817397A2 (pt) | 2015-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3406251B1 (en) | Pyruvate kinase activators for use in therapy | |
| JP6502919B2 (ja) | アミドピリジンオール誘導体またはその薬剤学的に許容可能な塩、及びそれを有効成分として含有する薬学組成物 | |
| JP2014518554A (ja) | スフィンゴシン−1リン酸受容体調節剤としての置換二環式メチルアミン誘導体 | |
| US7888336B2 (en) | Indole compounds bearing aryl or heteroaryl groups having sphingosine 1-phosphate (S1P) receptor biological activity | |
| US8049037B2 (en) | Sphingosine-1-phosphate (S1P) receptor antagonists and methods for use thereof | |
| US8318783B2 (en) | 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators | |
| US8143291B2 (en) | Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity | |
| JP2014062103A (ja) | 治療用キノリンおよびナフタレン誘導体 | |
| EP2646027B1 (en) | Novel pyridine derivatives as sphingosine 1-phosphate (s1p) receptor modulators | |
| HK40000845B (en) | Pyruvate kinase activators for use in therapy | |
| HK40000845A (en) | Pyruvate kinase activators for use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |